2022年考研英语命题预测模拟试题(二)(3).docx

上传人:ni****g 文档编号:561318901 上传时间:2023-12-04 格式:DOCX 页数:3 大小:12.35KB
返回 下载 相关 举报
2022年考研英语命题预测模拟试题(二)(3).docx_第1页
第1页 / 共3页
2022年考研英语命题预测模拟试题(二)(3).docx_第2页
第2页 / 共3页
2022年考研英语命题预测模拟试题(二)(3).docx_第3页
第3页 / 共3页
亲,该文档总共3页,全部预览完了,如果喜欢就下载吧!
资源描述

《2022年考研英语命题预测模拟试题(二)(3).docx》由会员分享,可在线阅读,更多相关《2022年考研英语命题预测模拟试题(二)(3).docx(3页珍藏版)》请在金锄头文库上搜索。

1、 2022年考研英语命题预测模拟试题(二)(3) Part C Directions: Read the following text carefully and then translate the underlined segments into Chinese. Your translation should be written clearly on ANSWER SHEET 2. (10points) Biotech firms are no longer mere fodder for the pharmaceutical giants AMGEN, the world”s big

2、gest biotechnology company, made its fortune from a drug that fortifies the blood of patients who are undergoing dialysis. On December 17th, the California company acquired some new blood of its own with the purchase of Immunex, a Seattle-based biotechnology company, for $16 billion. This deal, a bi

3、otech-industry record, gives Amgen a firm footing in the multibillion-dollar market in inflammation control. Immunex”s most lucrative product is Enbrel, a treatment for rheumatoid arthritis.(46) Amgen hopes to triple the drug”s sales to more than $3 billion by 2022, widening its use to other disease

4、s, such as psoriasis, and overcoming manufacturing constraints that have kept the drug in short supply. With this takeover, Immunex passes from one parent to another. American Home Products (AHP) holds 41% of the shares, and has given the firm sales and marketing support. (47)But AHP has been sellin

5、g down its stake since last year, in part to finance a $3.8 billion settlement of claims against its diet drugs. (48)Although Amgen calls itself a biotech company, its market capitalisation of around $62 billion makes it larger than Pharmacia and several other well-known mainstream drug companies, t

6、raditionally considered the big brothers of biotech. But Amgen likes to think of itself as less bureaucratic and more entrepreneurial than its pharmaceutical brethren, and it is free of such big-pharma woes as imminent patent expiry. (49)However, as Joseph Dougherty, a biotech analyst at Lehman Brothers, points out, Amgen will find it hard to retain the freedom of its nimble youth as it strives to expand its sales by more than 30% a year.

展开阅读全文
相关资源
相关搜索

当前位置:首页 > 高等教育 > 大学课件

电脑版 |金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号